June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Role of additional dexamethasone treatment for the management of persistent choroidal neovascularization secondary to age-related macular degeneration
Author Affiliations & Notes
  • Sandra Rezar
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Stefan Sacu
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Katharina Eibenberger
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Wolf Bühl
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Christoph Krall
    Medical University of Vienna, Department of Medical Statistics, Vienna, Austria
  • Guenther Weigert
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Ursula Schmidt-Erfurth
    Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria
  • Footnotes
    Commercial Relationships Sandra Rezar, None; Stefan Sacu, Allergan (F), Askin (F), Bayer (F), Novartis (F), Pharmaselekt (F); Katharina Eibenberger, None; Wolf Bühl, None; Christoph Krall, None; Guenther Weigert, None; Ursula Schmidt-Erfurth, Alcon (F), Bayer (F), Böhringer-Ingelheim (F), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1280. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sandra Rezar, Stefan Sacu, Katharina Eibenberger, Wolf Bühl, Christoph Krall, Guenther Weigert, Ursula Schmidt-Erfurth, ; Role of additional dexamethasone treatment for the management of persistent choroidal neovascularization secondary to age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1280.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: As persistent or recurrent neovascular age-related macular degeneration (nAMD) is a frequent condition requiring continuous re-treatment, efficacy and safety of an adjuvant treatment modality using a combination of dexamethasone and ranibizumab was compared with a ranibizumab monotherapy.

Methods: 40 eyes of 38 consecutive patients were enrolled in this 12-month, prospective, randomized clinical trial. We randomly assigned the patients (1:1) defined as nAMD with persistent intraretinal and/or subfoveal fluid after ranibizumab treatment seen on optical coherence tomography (OCT) to receive either intravitreal ranibizumab monotherapy (IVM) or dexamethasone and ranibizumab combination therapy (IVC). In the second group a dexamethasone intravitreal implant was additionally administered at baseline and after 6 months earliest in case of missing disease stability. Primary outcome measurements were re-treatment rate of the patients and change in functional parameters.

Results: Patients were included after mean of 11.7/11.9 (IVM/IVC) months after initial treatment and received a mean amount of 5.6±3.4/6.7±4.4 ranibizumab injections before inclusion. After 4 weeks 14 re-treatments were given in the IVM group versus 7 in the IVC group and after 8 weeks 17/8 (IVC/IVM). Median time until the second ranibizumab re-treatment differed significantly (p=0.0042; logrank-test). Functional parameter remained stable in both groups with no significant differences (visual acuity: 62/68 seen letters at baseline; 67/68 after 12 months, p=0.68; macular sensitivity: 6.95/7.24 and 7.01/7.12dB, p=0.4). Central retinal thickness decreased, however, with no significance between the groups (486/439 at baseline; 453/368 after 12 months; p=0.38). 3 patients required topical pressure medication during the study period and 1/4 patients (IVM/IVC) were referred to cataract surgery after study completion.

Conclusions: Adding dexamethasone to ranibizumab treatment in persistent nAMD cases seems to delay re-treatment with ranibizumab. Combined treatment with dexamethasone should be considered in selected cases. Non-superiorities in functional parameter were observed over the 12 months period.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×